펩타이드 및 항응고제 시장 규모는 향후 몇 년 동안 급성장할 것으로 예상됩니다. 2029년에는 10.3%의 연평균 성장률(CAGR)로 23억 3천만 달러까지 성장할 것으로 예상됩니다. 예측 기간 동안의 성장은 만성 질환의 유병률 증가, 인구 고령화, 암 발병률 증가, 신흥 시장의 확대, 심혈관 질환의 부담 증가에 기인할 수 있습니다. 이 기간 동안 예상되는 주요 트렌드에는 생명공학의 발전, 약물 전달 기술 개발, 진단 기술 개선, 약리학의 혁신, 새로운 항응고제 제품 개발 등이 있습니다.
만성 질환의 유병률 증가는 펩타이드 및 항응고제 시장의 성장을 견인할 것으로 예상됩니다. 만성 질환은 수년 또는 평생 동안 지속되는 장기적인 건강 상태입니다. 인구 고령화, 건강에 해로운 생활 습관, 비만, 고혈압, 당뇨병과 같은 위험 요인의 증가와 같은 요인이 만성 질환의 부담을 증가시키는 데 기여합니다. 펩타이드 및 항응고제는 혈전을 예방하고 특정 질병 경로를 표적으로 삼아 환자의 치료 결과를 개선함으로써 심혈관 질환, 혈전증, 뇌졸중과 같은 질환을 관리하는 데 중요한 역할을 합니다. 예를 들어 2023년 5월 미국 질병예방관리센터(CDC)의 보고에 따르면 2022년 심장병 및 암으로 인한 사망자 수는 2021년 60만 5,213명에서 69만 5,547명으로 증가했습니다. 결과적으로 만성 질환의 유병률 증가는 펩타이드 및 항응고제 시장의 확장을 촉진하고 있습니다.
펩타이드 및 항응고제 시장의 기업들은 효능을 높이고 환자 순응도를 개선하며 출혈 합병증의 위험을 줄이기 위해 경구용 항응고제와 같은 항응고제 치료법의 발전에 집중하고 있습니다. 경구용 항응고제는 혈액 내 응고 인자를 억제하여 혈전을 예방하기 위해 경구로 복용하는 약물입니다. 예를 들어, 2024년 4월 미국 제약 회사인 Cadrenal Therapeutics는 후기 단계 경구용 항응고제인 테카르파린에 대해 미국 식품의약국(FDA)으로부터 희귀의약품 지정(ODD)을 받았습니다. 테카파린은 희귀 심혈관 질환 환자의 심장마비, 뇌졸중 및 혈전과 관련된 사망 위험을 줄이기 위해 설계된 새로운 가역성 혈액 희석제입니다. 특히 좌심실 보조 장치(LVAD), 우심실 보조 장치(RVAD), 심실 보조 장치(VAD), 양심실 보조 장치 및 전체 인공 심장을 포함한 기계적 순환 지원 장치를 이식한 환자의 혈전 색전증 및 혈전증 예방에 적용됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 펩타이드 및 항응고제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업의 분석
- 세계의 펩타이드 및 항응고제 시장 : 성장률 분석
- 세계의 펩타이드 및 항응고제 시장 실적 : 규모와 성장(2019-2024년)
- 세계의 펩타이드 및 항응고제 시장 예측 : 규모와 성장(2024-2029년, 2034년)
- 세계의 펩타이드 및 항응고제 총 시장 규모(TAM)
제6장 시장 세분화
- 세계의 펩타이드 및 항응고제 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 호르몬
- 항생제
- ACE 억제제
- 항진균제
- 기타
- 세계의 펩타이드 및 항응고제 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 경구
- 주사제
- 기타 투여 경로
- 세계의 펩타이드 및 항응고제 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 병원 약국
- 소매 약국
- 온라인 약국
- 기타 유통 채널
- 세계의 펩타이드 및 항응고제 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 감염증
- 부인과
- 암
- 당뇨병
- 심장병학
- 골다공증
- 기타 용도
- 세계의 펩타이드 및 항응고제 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 병원
- 전문 클리닉
- 홈케어
- 기타 최종 사용자
- 세계의 펩타이드 및 항응고제 시장 : 호르몬 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 펩티드 호르몬
- 스테로이드 호르몬
- 갑상선 호르몬
- 세계의 펩타이드 및 항응고제 시장 : 항생제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 베타-락탐
- 마크로라이드
- 테트라 사이클린
- 플루오로퀴놀론
- 기타 항생제
- 세계의 펩타이드 및 항응고제 시장 : ACE 억제제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 캡토프릴
- 에날라프릴
- 리시노프릴
- 라미프릴
- 기타 ACE 억제제
- 세계의 펩타이드 및 항응고제 시장 : 항진균제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 아졸
- 에키노칸딘
- 폴리엔
- 알릴아민
- 기타 항진균제
- 세계의 펩타이드 및 항응고제 시장 : 기타 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 면역 억제제
- 항종양제
- 심혈관제
- 기타 펩타이드 및 항응고제
제7장 지역별 및 국가별 분석
- 세계의 펩타이드 및 항응고제 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 펩타이드 및 항응고제 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
- 펩타이드 및 항응고제 시장 : 경쟁 구도
- 펩타이드 및 항응고제 시장 : 기업 프로파일
- Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- Merck & Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- Bayer AG 개요, 제품 및 서비스, 전략 및 재무 분석
- F. Hoffmann-La Roche Ltd 개요, 제품 및 서비스, 전략 및 재무 분석
- Sanofi SA 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Abbott Laboratories
- Novartis AG
- Novo Nordisk A/S
- Viatris Inc.
- Baxter International Inc.
- Boehringer Ingelheim International GmbH
- Sun Pharmaceutical Industries Limited
- Bachem Holding AG
- Bharat Serums and Vaccines Limited
- Wockhardt Limited
- AmbioPharm Inc.
- MITS Healthcare Private Limited
- Siddha Pharmacy
- Circle Pharma Inc.
- Tenwel Pharmaceuticals Pvt. Ltd.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 펩타이드 및 항응고제 시장(2029년) : 새로운 기회를 제공하는 국가
- 펩타이드 및 항응고제 시장(2029년) : 새로운 기회를 제공하는 부문
- 펩타이드 및 항응고제 시장(2029년) : 성장 전략
제36장 부록
HBR
Peptide and anticoagulant drugs are therapeutic agents where peptide drugs are short chains of amino acids that mimic natural biological molecules, and anticoagulant drugs prevent blood clotting by inhibiting clotting factors. Some anticoagulants, such as hirudin and bivalirudin, are peptide-based, directly inhibiting thrombin to prevent thrombosis. These drugs are crucial in treating conditions such as deep vein thrombosis, pulmonary embolism, and stroke.
The main types of peptide and anticoagulant drugs are hormonal, antibiotic, ACE inhibitor, antifungal, and other types. Hormonal drugs, including peptide-based hormones such as insulin and GLP-1 analogs, regulate hormone levels to treat conditions such as diabetes, while peptide and anticoagulant drugs provide targeted therapies for managing chronic diseases. These drugs can be administered through various routes, including oral, injectable, and other methods, and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and others. Their applications span a wide range of medical fields, including infectious diseases, gynecology, cancer, diabetes, cardiology, osteoporosis, and others. End-users of these drugs include hospitals, specialty clinics, home care settings, and others.
The peptide and anticoagulant drugs market research report is one of a series of new reports from The Business Research Company that provides peptide and anticoagulant drugs market statistics, including the peptide and anticoagulant drugs industry global market size, regional shares, competitors with the peptide and anticoagulant drugs market share, detailed peptide and anticoagulant drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the peptide and anticoagulant drugs industry. This peptide and anticoagulant drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The peptide and anticoagulant drugs market size has grown at grown rapidly in recent years. It will grow from $1.41 billion in 2024 to $1.56 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth during the historic period can be attributed to increased healthcare expenditure, rising healthcare investments, market liberalization, a growing number of infected patients worldwide, and a higher incidence of genetic conditions.
The peptide and anticoagulant drugs market size is expected to see rapid growth in the next few years. It will grow to $2.30 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The growth during the forecast period can be attributed to the rising prevalence of chronic diseases, an aging population, increasing cancer cases, the expansion of emerging markets, and the growing burden of cardiovascular diseases. Key trends expected during this period include advancements in biotechnology, technological developments in drug delivery, improved diagnostic techniques, innovations in pharmacology, and the development of new anticoagulant products.
The increasing prevalence of chronic diseases is expected to drive the growth of the peptide and anticoagulant drugs market. Chronic diseases are long-term health conditions that persist for years or even a lifetime. Factors such as aging populations, unhealthy lifestyles, and a rise in risk factors such as obesity, hypertension, and diabetes contribute to the growing burden of chronic diseases. Peptide and anticoagulant drugs play a crucial role in managing conditions such as cardiovascular diseases, thrombosis, and stroke by preventing blood clots and targeting specific disease pathways for better patient outcomes. For example, in May 2023, reports from the Centers for Disease Control and Prevention (CDC) indicated that heart disease and cancer deaths reached 695,547 in 2022, an increase from 605,213 in 2021. As a result, the rising prevalence of chronic diseases is fueling the expansion of the peptide and anticoagulant drugs market.
Companies in the peptide and anticoagulant drugs market are focusing on advancements in anticoagulant therapies, such as oral anticoagulants, to enhance efficacy, improve patient compliance, and reduce the risk of bleeding complications. Oral anticoagulants are medications taken by mouth to prevent blood clots by inhibiting clotting factors in the blood. For instance, in April 2024, Cadrenal Therapeutics Inc., a US-based pharmaceutical company, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for tecarfarin, its late-stage oral anticoagulant. Tecarfarin is a novel, reversible blood thinner designed to reduce the risk of heart attacks, strokes, and mortality associated with blood clots in patients with rare cardiovascular conditions. The ODD applies specifically to preventing thromboembolism and thrombosis in patients with implanted mechanical circulatory support devices, including left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), ventricular assist devices (VADs), biventricular assist devices, and total artificial hearts.
In September 2023, Biosynth, a Switzerland-based provider of complex chemicals and biological materials, acquired Pepceuticals for an undisclosed amount. This acquisition aims to strengthen Biosynth's capabilities in developing and manufacturing peptide-based therapeutics and biomaterials. The strategic move expands Biosynth's presence in the life sciences sector, offering a broader portfolio of advanced solutions for the pharmaceutical and biotechnology industries. Pepceuticals Ltd is a UK-based manufacturer specializing in synthetic peptides.
Major players in the peptide and anticoagulant drugs market are Pfizer Inc., Merck & Co. Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Sanofi S.A., Abbott Laboratories, Novartis AG, Novo Nordisk A/S, Viatris Inc., Baxter International Inc., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Bachem Holding AG, Bharat Serums and Vaccines Limited, Wockhardt Limited, AmbioPharm Inc., MITS Healthcare Private Limited, Siddha Pharmacy, Circle Pharma Inc., and Tenwel Pharmaceuticals Pvt. Ltd.
North America was the largest region in the peptide and anticoagulant drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in peptide and anticoagulant drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the peptide and anticoagulant drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The peptide and anticoagulant drugs market consists of sales of peptide-based drugs and heparins. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Peptide And Anticoagulant Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on peptide and anticoagulant drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for peptide and anticoagulant drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The peptide and anticoagulant drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Hormonal; Antibiotic; Ace Inhibitor; Antifungal; Other Types
- 2) By Route Of Administration: Oral; Injectable; Other Routes Of Administration
- 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
- 4) By Application: Infectious Diseases; Gynecology; Cancer; Diabetes; Cardiology; Osteoporosis; Other Applications
- 5) By End-users: Hospitals; Specialty Clinics; Homecare; Other End-users
- Subsegments:
- 1) By Hormonal: Peptide Hormones; Steroid Hormones; Thyroid Hormones; Other Hormones
- 2) By Antibiotic: Beta-Lactams; Macrolides; Tetracyclines; Fluoroquinolones; Other Antibiotics
- 3) By ACE Inhibitor: Captopril; Enalapril; Lisinopril; Ramipril; Other ACE Inhibitors
- 4) By Antifungal: Azoles; Echinocandins; Polyenes; Allylamines; Other Antifungals
- 5) By Other Types: Immunosuppressants; Antineoplastic Agents; Cardiovascular Drugs; Other Peptide And Anticoagulant Drugs
- Companies Mentioned:Pfizer Inc.; Merck & Co. Inc.; Bayer AG; F. Hoffmann-La Roche Ltd; Sanofi S.A.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Peptide And Anticoagulant Drugs Market Characteristics
3. Peptide And Anticoagulant Drugs Market Trends And Strategies
4. Peptide And Anticoagulant Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Peptide And Anticoagulant Drugs Growth Analysis And Strategic Analysis Framework
- 5.1. Global Peptide And Anticoagulant Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Peptide And Anticoagulant Drugs Market Growth Rate Analysis
- 5.4. Global Peptide And Anticoagulant Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Peptide And Anticoagulant Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Peptide And Anticoagulant Drugs Total Addressable Market (TAM)
6. Peptide And Anticoagulant Drugs Market Segmentation
- 6.1. Global Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hormonal
- Antibiotic
- Ace Inhibitor
- Antifungal
- Other Types
- 6.2. Global Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Injectable
- Other Routes Of Administration
- 6.3. Global Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Other Distribution Channels
- 6.4. Global Peptide And Anticoagulant Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Infectious Diseases
- Gynecology
- Cancer
- Diabetes
- Cardiology
- Osteoporosis
- Other Applications
- 6.5. Global Peptide And Anticoagulant Drugs Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Specialty Clinics
- Homecare
- Other End-users
- 6.6. Global Peptide And Anticoagulant Drugs Market, Sub-Segmentation Of Hormonal, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Peptide Hormones
- Steroid Hormones
- Thyroid Hormones
- 6.7. Global Peptide And Anticoagulant Drugs Market, Sub-Segmentation Of Antibiotic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Beta-Lactams
- Macrolides
- Tetracyclines
- Fluoroquinolones
- Other Antibiotics
- 6.8. Global Peptide And Anticoagulant Drugs Market, Sub-Segmentation Of ACE Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Captopril
- Enalapril
- Lisinopril
- Ramipril
- Other ACE Inhibitors
- 6.9. Global Peptide And Anticoagulant Drugs Market, Sub-Segmentation Of Antifungal, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Azoles
- Echinocandins
- Polyenes
- Allylamines
- Other Antifungals
- 6.10. Global Peptide And Anticoagulant Drugs Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Immunosuppressants
- Antineoplastic Agents
- Cardiovascular Drugs
- Other Peptide And Anticoagulant Drugs
7. Peptide And Anticoagulant Drugs Market Regional And Country Analysis
- 7.1. Global Peptide And Anticoagulant Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Peptide And Anticoagulant Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Peptide And Anticoagulant Drugs Market
- 8.1. Asia-Pacific Peptide And Anticoagulant Drugs Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Peptide And Anticoagulant Drugs Market
- 9.1. China Peptide And Anticoagulant Drugs Market Overview
- 9.2. China Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Peptide And Anticoagulant Drugs Market
- 10.1. India Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Peptide And Anticoagulant Drugs Market
- 11.1. Japan Peptide And Anticoagulant Drugs Market Overview
- 11.2. Japan Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Peptide And Anticoagulant Drugs Market
- 12.1. Australia Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Peptide And Anticoagulant Drugs Market
- 13.1. Indonesia Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Peptide And Anticoagulant Drugs Market
- 14.1. South Korea Peptide And Anticoagulant Drugs Market Overview
- 14.2. South Korea Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Peptide And Anticoagulant Drugs Market
- 15.1. Western Europe Peptide And Anticoagulant Drugs Market Overview
- 15.2. Western Europe Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Peptide And Anticoagulant Drugs Market
- 16.1. UK Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Peptide And Anticoagulant Drugs Market
- 17.1. Germany Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Peptide And Anticoagulant Drugs Market
- 18.1. France Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Peptide And Anticoagulant Drugs Market
- 19.1. Italy Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Peptide And Anticoagulant Drugs Market
- 20.1. Spain Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Peptide And Anticoagulant Drugs Market
- 21.1. Eastern Europe Peptide And Anticoagulant Drugs Market Overview
- 21.2. Eastern Europe Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Peptide And Anticoagulant Drugs Market
- 22.1. Russia Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Peptide And Anticoagulant Drugs Market
- 23.1. North America Peptide And Anticoagulant Drugs Market Overview
- 23.2. North America Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Peptide And Anticoagulant Drugs Market
- 24.1. USA Peptide And Anticoagulant Drugs Market Overview
- 24.2. USA Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Peptide And Anticoagulant Drugs Market
- 25.1. Canada Peptide And Anticoagulant Drugs Market Overview
- 25.2. Canada Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Peptide And Anticoagulant Drugs Market
- 26.1. South America Peptide And Anticoagulant Drugs Market Overview
- 26.2. South America Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Peptide And Anticoagulant Drugs Market
- 27.1. Brazil Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Peptide And Anticoagulant Drugs Market
- 28.1. Middle East Peptide And Anticoagulant Drugs Market Overview
- 28.2. Middle East Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Peptide And Anticoagulant Drugs Market
- 29.1. Africa Peptide And Anticoagulant Drugs Market Overview
- 29.2. Africa Peptide And Anticoagulant Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Peptide And Anticoagulant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Peptide And Anticoagulant Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Peptide And Anticoagulant Drugs Market Competitive Landscape And Company Profiles
- 30.1. Peptide And Anticoagulant Drugs Market Competitive Landscape
- 30.2. Peptide And Anticoagulant Drugs Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
31. Peptide And Anticoagulant Drugs Market Other Major And Innovative Companies
- 31.1. Abbott Laboratories
- 31.2. Novartis AG
- 31.3. Novo Nordisk A/S
- 31.4. Viatris Inc.
- 31.5. Baxter International Inc.
- 31.6. Boehringer Ingelheim International GmbH
- 31.7. Sun Pharmaceutical Industries Limited
- 31.8. Bachem Holding AG
- 31.9. Bharat Serums and Vaccines Limited
- 31.10. Wockhardt Limited
- 31.11. AmbioPharm Inc.
- 31.12. MITS Healthcare Private Limited
- 31.13. Siddha Pharmacy
- 31.14. Circle Pharma Inc.
- 31.15. Tenwel Pharmaceuticals Pvt. Ltd.
32. Global Peptide And Anticoagulant Drugs Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Peptide And Anticoagulant Drugs Market
34. Recent Developments In The Peptide And Anticoagulant Drugs Market
35. Peptide And Anticoagulant Drugs Market High Potential Countries, Segments and Strategies
- 35.1 Peptide And Anticoagulant Drugs Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Peptide And Anticoagulant Drugs Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Peptide And Anticoagulant Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
